Trabecular reorganization in consecutive iliac crest biopsies when switching from bisphosphonate to strontium ranelate treatment.

BACKGROUND: Several agents are available to treat osteoporosis while addressing patient-specific medical needs. Individuals' residual risk to severe fracture may require changes in treatment strategy. Data at osseous cellular and microstructural levels due to a therapy switch between agents wit...

Full description

Bibliographic Details
Main Authors: Björn Jobke, Andrew J Burghardt, Burkhard Muche, Michael Hahn, Jutta Semler, Michael Amling, Sharmila Majumdar, Björn Busse
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2011-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3156767?pdf=render
_version_ 1818141392566747136
author Björn Jobke
Andrew J Burghardt
Burkhard Muche
Michael Hahn
Jutta Semler
Michael Amling
Sharmila Majumdar
Björn Busse
author_facet Björn Jobke
Andrew J Burghardt
Burkhard Muche
Michael Hahn
Jutta Semler
Michael Amling
Sharmila Majumdar
Björn Busse
author_sort Björn Jobke
collection DOAJ
description BACKGROUND: Several agents are available to treat osteoporosis while addressing patient-specific medical needs. Individuals' residual risk to severe fracture may require changes in treatment strategy. Data at osseous cellular and microstructural levels due to a therapy switch between agents with different modes of action are rare. Our study on a series of five consecutively taken bone biopsies from an osteoporotic individual over a six-year period analyzes changes in cellular characteristics, bone microstructure and mineralization caused by a therapy switch from an antiresorptive (bisphosphonate) to a dual action bone agent (strontium ranelate). METHODOLOGY/PRINCIPAL FINDINGS: Biopsies were progressively taken from the iliac crest of a female patient. Four biopsies were taken during bisphosphonate therapy and one biopsy was taken after one year of strontium ranelate (SR) treatment. Furthermore, serum bone markers and dual x-ray absorptiometry measurements were acquired. Undecalcified histology was used to assess osteoid parameters and bone turnover. Structural indices and degree of mineralization were determined using microcomputed tomography, quantitative backscattered electron imaging, and combined energy dispersive x-ray/µ-x-ray-fluorescence microanalysis. CONCLUSIONS/SIGNIFICANCE: Microstructural data revealed a notable increase in bone volume fraction after one year of SR treatment compared to the bisphosphonate treatment period. Indices of connectivity density, structure model index and trabecular bone pattern factor were predominantly enhanced indicating that the architectural transformation from trabecular rods to plates was responsible for the bone volume increase and less due to changes in trabecular thickness and number. Administration of SR following bisphosphonates led to a maintained mineralization profile with an uptake of strontium on the bone surface level. Reactivated osteoclasts designed tunneling, hook-like intratrabecular resorption sites. The appearance of tunneling resorption lacunae and the formation of both mini-modeling units and osteon-like structures within increased plate-like cancellous bone mass provides additional information on the mechanisms of strontium ranelate following bisphosphonate treatment, which may deserve special attention when monitoring a treatment switch.
first_indexed 2024-12-11T10:59:09Z
format Article
id doaj.art-becc9f73163a4c4aaacea65a2bea7582
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-11T10:59:09Z
publishDate 2011-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-becc9f73163a4c4aaacea65a2bea75822022-12-22T01:09:57ZengPublic Library of Science (PLoS)PLoS ONE1932-62032011-01-0168e2363810.1371/journal.pone.0023638Trabecular reorganization in consecutive iliac crest biopsies when switching from bisphosphonate to strontium ranelate treatment.Björn JobkeAndrew J BurghardtBurkhard MucheMichael HahnJutta SemlerMichael AmlingSharmila MajumdarBjörn BusseBACKGROUND: Several agents are available to treat osteoporosis while addressing patient-specific medical needs. Individuals' residual risk to severe fracture may require changes in treatment strategy. Data at osseous cellular and microstructural levels due to a therapy switch between agents with different modes of action are rare. Our study on a series of five consecutively taken bone biopsies from an osteoporotic individual over a six-year period analyzes changes in cellular characteristics, bone microstructure and mineralization caused by a therapy switch from an antiresorptive (bisphosphonate) to a dual action bone agent (strontium ranelate). METHODOLOGY/PRINCIPAL FINDINGS: Biopsies were progressively taken from the iliac crest of a female patient. Four biopsies were taken during bisphosphonate therapy and one biopsy was taken after one year of strontium ranelate (SR) treatment. Furthermore, serum bone markers and dual x-ray absorptiometry measurements were acquired. Undecalcified histology was used to assess osteoid parameters and bone turnover. Structural indices and degree of mineralization were determined using microcomputed tomography, quantitative backscattered electron imaging, and combined energy dispersive x-ray/µ-x-ray-fluorescence microanalysis. CONCLUSIONS/SIGNIFICANCE: Microstructural data revealed a notable increase in bone volume fraction after one year of SR treatment compared to the bisphosphonate treatment period. Indices of connectivity density, structure model index and trabecular bone pattern factor were predominantly enhanced indicating that the architectural transformation from trabecular rods to plates was responsible for the bone volume increase and less due to changes in trabecular thickness and number. Administration of SR following bisphosphonates led to a maintained mineralization profile with an uptake of strontium on the bone surface level. Reactivated osteoclasts designed tunneling, hook-like intratrabecular resorption sites. The appearance of tunneling resorption lacunae and the formation of both mini-modeling units and osteon-like structures within increased plate-like cancellous bone mass provides additional information on the mechanisms of strontium ranelate following bisphosphonate treatment, which may deserve special attention when monitoring a treatment switch.http://europepmc.org/articles/PMC3156767?pdf=render
spellingShingle Björn Jobke
Andrew J Burghardt
Burkhard Muche
Michael Hahn
Jutta Semler
Michael Amling
Sharmila Majumdar
Björn Busse
Trabecular reorganization in consecutive iliac crest biopsies when switching from bisphosphonate to strontium ranelate treatment.
PLoS ONE
title Trabecular reorganization in consecutive iliac crest biopsies when switching from bisphosphonate to strontium ranelate treatment.
title_full Trabecular reorganization in consecutive iliac crest biopsies when switching from bisphosphonate to strontium ranelate treatment.
title_fullStr Trabecular reorganization in consecutive iliac crest biopsies when switching from bisphosphonate to strontium ranelate treatment.
title_full_unstemmed Trabecular reorganization in consecutive iliac crest biopsies when switching from bisphosphonate to strontium ranelate treatment.
title_short Trabecular reorganization in consecutive iliac crest biopsies when switching from bisphosphonate to strontium ranelate treatment.
title_sort trabecular reorganization in consecutive iliac crest biopsies when switching from bisphosphonate to strontium ranelate treatment
url http://europepmc.org/articles/PMC3156767?pdf=render
work_keys_str_mv AT bjornjobke trabecularreorganizationinconsecutiveiliaccrestbiopsieswhenswitchingfrombisphosphonatetostrontiumranelatetreatment
AT andrewjburghardt trabecularreorganizationinconsecutiveiliaccrestbiopsieswhenswitchingfrombisphosphonatetostrontiumranelatetreatment
AT burkhardmuche trabecularreorganizationinconsecutiveiliaccrestbiopsieswhenswitchingfrombisphosphonatetostrontiumranelatetreatment
AT michaelhahn trabecularreorganizationinconsecutiveiliaccrestbiopsieswhenswitchingfrombisphosphonatetostrontiumranelatetreatment
AT juttasemler trabecularreorganizationinconsecutiveiliaccrestbiopsieswhenswitchingfrombisphosphonatetostrontiumranelatetreatment
AT michaelamling trabecularreorganizationinconsecutiveiliaccrestbiopsieswhenswitchingfrombisphosphonatetostrontiumranelatetreatment
AT sharmilamajumdar trabecularreorganizationinconsecutiveiliaccrestbiopsieswhenswitchingfrombisphosphonatetostrontiumranelatetreatment
AT bjornbusse trabecularreorganizationinconsecutiveiliaccrestbiopsieswhenswitchingfrombisphosphonatetostrontiumranelatetreatment